The mRNA skills we used to fight COVID can help us fight malaria
The scientists’ response to COVID-19 was no less than Herculean. against the virus within a year – – and we have an mRNA expertise thanks for this. Finding that, instead of injecting ourselves with deadly viruses, we can trick our bodies into making our immune system by encouraging them to make proteins that have made drastic changes in the immune system. As the current epidemic vaccine rises, medical professionals hope to turn this powerful weapon into a more effective vaccine. And .
“The vaccine component has been changed permanently and has gone on indefinitely thanks to COVID-19,” Drs. Dan Barouch, director of the Center for Virology and Vaccine Research at Harvard Medical School, said in March.
According to , about 290 million people get malaria each year and at least 400,000 people die from the disease each year – especially young children, the elderly and the sick – which makes the disease more prevalent worldwide. Symptoms include constant “suffering” – chills and chills followed by fever followed by chills followed by fever.
“Safe, effective, affordable vaccines can play a significant role in the fight against malaria,” said Dr Robert Newman, Director of WHO’s. he said in 2013. “Although countries have made great strides, and despite the discovery of new methods of research on drugs, drugs and combating vectors, the problem of malaria worldwide has become more widespread.”
Researchers have been studying the Malaria vaccine since its first discovery in 1897. However, progress has been slow and the reasons for this are, “a few of which are in the presence of the virus, which explains more than 5,000 proteins in its various stages, difficult links between biology germs and disease prevention, lack of adequate weapons and a lack of international cooperation, ”wrote Giampietro Corradin and Andrey Kajava, professors at the University of Lausanne and the University of Montpellier, respectively, in 2014.
But is fixing to turn that power on his ear. In a report published in the April issue of , Mehreen Datoo, author and research fellow at the Jenner Institute of Oxford, and his team revealed that they have developed a vaccine candidate who showed 77% efficacy after 12 months of inoculation. At the very least, it acted as part of its Phase IIb test, which includes more than 450 children, ages 5-17, living in Burkina Faso. Named , this indicates the first time that such treatment has been met or continued 75% effective goal.
‘Malaria is one of the leading causes of child mortality in Africa, “said Professor Charlemagne Ouédraogo, Minister of Health in Burkina Faso. in April. “We have been supporting various vaccine trials in Burkina Faso and this shows that the introduction of a new malaria vaccine could be done in the coming years. It could be a very important tool to eradicate malaria and save many lives.”
The results are very encouraging, researchers (according to ) has already started writing Phase III exams with 4,800 children, aged 5-36, in four African countries. And we have the expertise of mRNA thanks for this.
The first advantage of mRNA supplementation over those who make the drug is that the genetic pathway can be found, says Drs. Stephen Floor, Assistant Professor at UCSF’s department of Cell & Tissue Biology, is leading the researcher at which is in it.
“If you are developing a small molecule of culture or anti-retroviral drugs, there is a lot of optimization and development that needs to be done,” he said. “And often the rules are not properly interpreted. You cannot say, ‘because this molecule worked well with this protein, I predict that this other molecule will work in a similar protein.’ ”
DNA – a gene that always produces ‘Idiocracy’ – the constant pattern of refusing to slip on jimmy – is made up of twin twins, shown, connected by two amino acids. Basically, small groups of animals that tell your kids how to make more of themselves, hopefully the more profitable they make seem less like your famous king.
However, with mRNA, “we understand the rules on how to synthesize proteins,” Floor continued, although we have not yet found a way to train mRNA to deal with other cells. Unfortunately, when it comes to antibodies, targeting is not necessary because your immune system does not care where the protein came from, it just acts as an external threat. “That’s why it’s been so effective at COVID,” he said. “That’s why it has to be useful in so many other places.”
The rest of the trip is a lot. Such mRNA drugs have already been tested for viruses from the flu to Zika, rabies, tuberculosis, hepatitis B, cystic fibrosis, HIV () – even cancer. , mRNA-induced therapy stimulates the patient’s cells to produce protein molecules that mimic the genetics of the tumor similar to the COVID vaccine that found cells to regenerate global viral spikes, as well as the same immune responses.
“The mRNA vaccine can be used to fight any viral infections,” Drs. John Cooke, executive director of the RNA Therapeutics Program at the Houston Methodist Research Institute, said AAMC. “You make a label for a specific protein that protects the immune system. … It is infinite. ”
But be aware that this is not a silver bullet that you can use to fight any human disease. Nor will it be made anywhere near the Moderna vaccine and Pfizer COVID. These researchers have been working on the HIV vaccine for 30 years so far with little progress to show. Although mRNA technology can significantly shorten the duration of treatment, “I don’t think we will finally get every vaccine in one year,” Drs. Florian Krammer, from the Icahn School of Medicine at Mount Sinai in New York, warned.
All products selected by Engadget are selected by our publishing team, excluding our parent company. Some of our articles include helpful links. If you purchase one of these links, we will be able to make a donation.